FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

October 10, 2017: By Joan McKenna

SparkSpark Therapeutics’ gene therapy candidate for inherited retinal disease will be reviewed Oct. 12 by the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee.

The panel will consider whether to recommend voretigene neparvovec, branded Luxturna, for the treatment of patients with vision loss due to retinal dystrophy caused by flaws in the RPE65 gene.

Spark says the gene mutation breaks the visual cycle of light activating photoreceptors, resulting in progressive vision loss and often near blindness.

The FDA has granted orphan drug, breakthrough therapy, and rare pediatric disease designations for voretigene neparvovec, a one-time treatment.

Spark estimates that disease affects an estimated 1 thousand to 3 thousand patients in the US.

Philadelphia-based Spark, founded in March 2013, now has a workforce of 300 industry professionals and has secured $1 billion in financing. It has a pipeline of eight investigational gene therapies. Luxturna is its lead candidate.

The panel meeting will run 8:30 to 5 p.m. Oct. 12 at the FDA’s White Oak Campus in Silver Spring, Maryland.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023